(Q37902488)

25 August 2017

1 reference

title

Pharmacokinetics of heparin and low molecular weight heparin (English)

1 reference

25 August 2017

1 reference

1 reference

Boneu B

1

1 reference

PubMed ID

2176903

25 August 2017

Caranobe C

series ordinal

2

1 reference

PubMed ID

2176903

25 August 2017

Sie P

series ordinal

3

1 reference

25 August 2017

1 July 1990

1 reference

Best Practice and Research: Clinical Haematology

25 August 2017

1 reference

25 August 2017

3

1 reference

25 August 2017

3

1 reference

25 August 2017

531-544

1 reference

Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Binding and endocytosis of heparin by human endothelial cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Endothelial binding sites for heparin. Specificity and role in heparin neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin degradation in the endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Prediction of heparin requirements in acute thromboplastic venous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

An objective study of alternative methods of heparin administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin kinetics determined by three assay methods

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin fractions with high and low affinities to antithrombin III are cleared at different rates

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin kinetics: variables related to disposition and dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Catabolism of low-dose heparin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Circadian changes in anticoagulant effect of heparin infused at a constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin requirements in pulmonary embolism and venous thrombosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The effect of molecular weight on the bioavailability of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The heterogeneity of the anticoagulant response to heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Binding of heparin on the surface of cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Low molecular weight heparin half life is prolonged in haemodialysed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The observation of heparin on endothelium after injection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin kinetics in venous thrombosis and pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Vascular sequestration of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Physiological factors concerned with the removal of injected heparin from the circulating blood

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The elimination from plasma of intravenous heparin. An experimental study on dogs and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

The fate of heparin in rabbits after intravenous injection; filtration and tubular secretion in the kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Circadian changes in anticoagulant effect of heparin infused at a constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Heparin pharmacokinetics: increased requirements in pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

Continuous heparin infusion requirements. Diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980017-4

7 January 2021

10.1016/S0950-3536(05)80017-4

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

2176903